Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

1. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.Journal of thoracic disease · 2022
   Review
2. Potential Morbidity Reduction for Lung Stereotactic Body Radiation Therapy Using Respiratory Gating.Cancers · 2021
   Article
3. Prediction of Local Recurrence Using Clinical and Radiomic Features in Lung Oligometastases Treated with Stereotactic Body Radiotherapy.Technology in cancer research & treatment
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

12 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as